Kyverna Therapeutics, Inc. (KYTX) stock
KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 3/30
$4.26−0.11 (-2.52%)
Close on Nov 20, 2026Market cap $263.45MP/E –Yield –
Kyverna Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Kyverna Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$163.10M. For fiscal 2025 it was -$169.83M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$169.83M | – |
| FY2024 | Dec 31, 2024 | -$142.60M | – |
| FY2023 | Dec 31, 2023 | -$62.41M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$42.90M | – |
| Q2 FY2026 | Jun 30, 2026 | -$39.56M | – |
| Q1 FY2026 | Mar 31, 2026 | -$41.37M | – |
| Q4 FY2025 | Dec 31, 2025 | -$39.28M | – |
| Q3 FY2025 | Sep 30, 2025 | -$38.73M | – |
| Q2 FY2025 | Jun 30, 2025 | -$44.41M | – |
| Q1 FY2025 | Mar 31, 2025 | -$47.41M | – |
| Q4 FY2024 | Dec 31, 2024 | -$41.04M | – |
| Q3 FY2024 | Sep 30, 2024 | -$38.77M | – |
| Q2 FY2024 | Jun 30, 2024 | -$33.44M | – |
| Q1 FY2024 | Mar 31, 2024 | -$29.36M | – |
| Q4 FY2023 | Dec 31, 2023 | -$21.38M | – |
| Q3 FY2023 | Sep 30, 2023 | -$16.28M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.30M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.45M | – |
See a number that looks wrong?